MONDAY, Feb. 11 (HealthDay News) -- The epilepsy drug
oxcarbazepine (Trileptal) does not seem to prevent migraines, as
once thought, a new study finds.
Migraines affect more than 28 million Americans, and certain
epilepsy drugs have been shown to be effective in preventing these
severe headaches. For this reason, many assumed that oxcarbazepine
would also work against migraines.
However, "the results of this trial do not support preliminary
data which had suggested oxcarbazepine was effective in preventing
migraine," lead researcher Dr. Stephen D. Silberstein, from Thomas
Jefferson University in Philadelphia, said in a statement. "While
several epilepsy drugs have been used for decades to prevent
migraine, oxcarbazepine did not prevent migraine in this study
despite it being shown to be safe and well-tolerated."
In the trial, 170 men and women took oxcarbazepine or placebo
daily for almost five months. All the people in the study suffered
from three to nine migraine attacks a month. Silberstein's team
found no difference between people taking oxcarbazepine or placebo
in the number of migraines they suffered during the study.
The report appears in the Feb. 12 issue of
Neurology.
"It's good to do these types of double-blind studies to assess
effectiveness of medications," said Dr. Walter J. Molofsky,
chairman of the Department of Neurology at Beth Israel Medical
Center in New York City.
"Since some antiepileptics are useful against migraine
headaches, it would be reasonable to assume that Trileptal would
work, too. This is an example of what is necessary to prove the
presence or absence of benefit," Molofsky said.
The three epilepsy drugs that have been shown to prevent
migraines, topiramate, divalproex and gabapentin, do so through
several mechanisms. One mechanism is the regulation of the
neurotransmitter called GABA. However, oxcarbazepine appears not to
affect GABA activity. It is possible that epilepsy drugs need to
regulate GABA to prevent migraine, Silberstein noted.
Another expert agreed that this drug is not likely to prevent
migraine.
"This is a study done by a group of experts in the field
following all the usual standards of clinical research, so the
findings can be accepted as valid," said Dr. Ellen Drexler,
director of the Headache Center at Maimonides Medical Center in New
York City. "The results are not that surprising, as drugs with
related mechanisms of action such as carbamazepine or phenytoin
have never been found to be efficacious for migraine
prophylaxis."
The study was paid for by Novartis Pharmaceuticals Corp., maker
of oxcarbazepine. Just last week , the U.S. Food and Drug
Administration warned that 11 epilepsy drugs, including
oxcarbazepine, might boost the risk of suicide among users.
More information
For more information on migraines, visit the
U.S. National Library of Medicine.